Lomefloxacin
JFDA label: Lomax 400mg Tab
Indications
Approved
- Bacterial Infections — bacterial disease
- Eye Infections — eye infection
Class profile
| gramStatus | Gram- |
|---|---|
| spectrumBreadth | Moderate |
| atypicalCoverage | No |
| isBactericidal | 1 |
| moaCategory | DNA synthesis inhibitor (topoisomerase II/IV) |
| pdIndex | Concentration-dependent |
| postAntibioticEffect | Prolonged |
| mrsaCoverage | 0 |
| resistanceMechanisms | Target site mutations (gyrA,parC),Active efflux |
Adverse Reactions
Nervous system disorders (8)
Common Dizziness · Headache
Rare Aphasia · Ataxia · Cerebral thrombosis · Myasthenia gravis · Neuropathy peripheral · Nystagmus
Hepatobiliary disorders (2)
Rare Hepatic necrosis · Hepatitis
Renal and urinary disorders (5)
Uncommon Blood creatinine increased
Rare Nephrolithiasis · Polyuria · Renal failure · Urinary retention
Blood and lymphatic system disorders (4)
Uncommon Eosinophilia · Leukopenia
Rare Agranulocytosis · Haemolytic anaemia
Immune system disorders (1)
Rare Anaphylactic shock
Gastrointestinal disorders (7)
Common Abdominal pain · Diarrhoea · Gastrointestinal pain · Nausea
Rare Hiccups · Intestinal perforation · Pseudomembranous colitis
Skin and subcutaneous tissue disorders (7)
Common Photosensitivity reaction
Rare Dermatitis exfoliative · Erythema multiforme · Erythema nodosum · Skin hyperpigmentation · Stevens-Johnson syndrome · Toxic epidermal necrolysis
Musculoskeletal and connective tissue disorders (1)
Rare Tendonitis
Psychiatric disorders (5)
Rare Anxiety · Hallucination · Mania · Phobia · Photophobia
Eye disorders (1)
Rare Diplopia
Investigations (3)
Uncommon Blood potassium decreased · Blood urea increased
Rare Urine output increased
General disorders and administration site conditions (9)
Uncommon Leukocytosis · Monocytosis
Rare Acidosis · Albuminuria · Candiduria · Crystalluria · Dysgeusia · Torsade de pointes · Vasculitis
Respiratory, thoracic and mediastinal disorders (3)
Rare Cardio-respiratory arrest · Pulmonary oedema · Tubulointerstitial nephritis
Pregnancy & Lactation
Pregnancy
Lactation
However, it is preferable to use an alternate drug for which safety information is available.
Monitoring
| Efficacy | Culture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin) |
|---|---|
| Toxicity | Renal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea) |
| Clinical pearl | Culture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship). |
| Counseling | Complete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h. |
Chemistry & Properties
| Formula | C17H19F2N3O3 |
|---|---|
| Molecular weight | 351.35 g/mol |
| IUPAC name | 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid |
| CAS | 98079-51-7 |
| PubChem CID | 3948 |
| InChIKey | ZEKZLJVOYLTDKK-UHFFFAOYSA-N |
| logP | 1.8 (XLogP -0.8) |
| Polar surface area | 74.57 Ų |
| H-bond acceptors / donors | 5 / 2 |
| Drug-likeness (QED) | 0.88 |
| Lipinski violations | 0 |
SMILES
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21Biology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 10.0% |
|---|---|
| Half-life | 1.964 h |
| Volume of distribution | 1.789 L/kg |
| Protein binding | 16.7% |
| BBB penetrant | No |
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP1A2 | Substrate | — |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OCTN1 (Inhibitor)OCTN2 (Inhibitor)P-gp (Inhibitor)MDR1 (Substrate)OATP1A2 (Substrate)P-gp (Substrate)Transporter(unspecified) (Substrate)
Drug–drug interactions (100+, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Anagrelide | major | |
| Arsenic trioxide | major | |
| Betamethasone | major | |
| Bupropion | major | |
| Cabozantinib | major | |
| Ceritinib | major | |
| Chloroquine | major | |
| Chlorpropamide | major | |
| Crizotinib | major | |
| Deflazacort | major | |
| Dexamethasone | major | |
| Dolasetron | major | |
| Fingolimod | major | |
| Fludrocortisone | major | |
| Glimepiride | major | |
| Glipizide | major | |
| Glyburide | major | |
| Hydrocortisone | major | |
| Hydroxychloroquine | major | |
| Insulin aspart (aspart) | major | |
| Insulin degludec | major | |
| Insulin detemir | major | |
| Insulin glargine | major | |
| Insulin glulisine | major | |
| Insulin human (inhalation, rapid acting) | major | |
| Insulin human (isophane) | major | |
| Insulin human (regular) | major | |
| Insulin human (zinc extended) | major | |
| Insulin human (zinc) | major | |
| Insulin lispro | major | |
| Iohexol | major | |
| Iopamidol | major | |
| Ivosidenib | major | |
| Lumefantrine | major | |
| Macimorelin | major | |
| Methylprednisolone | major | |
| Nateglinide | major | |
| Osimertinib | major | |
| Ozanimod | major | |
| Panobinostat | major |
Showing 40 of 100+.
Registered Products (3)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Orchacin Eye Drops | Ophthalmic Solution 3 mg/1 ml | 5 ml | Nabulsi Drug Store | 1.960 |
| Lomax | Tablet 400 mg | 5 tab pack varies | Professional Drug Store | 6.930 |
| Lomax | Tablet 400 mg | 10 tab pack varies | Professional Drug Store | 10.920 |